Edwards Lifesciences Corp Kürzel EW (WKN: 936853)
Seite 3 von 3 Neuester Beitrag: 04.12.24 18:28 | ||||
| Eröffnet am: | 03.11.16 21:06 | von: Tamakoschy | Anzahl Beiträge: | 52 |
| Neuester Beitrag: | 04.12.24 18:28 | von: Tamakoschy | Leser gesamt: | 35.320 |
| Forum: | Börse | Leser heute: | 18 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | > | ||||
Corporate News
Edwards Lifesciences Projects 2025 Constant Currency Sales Growth Of 8% - 10%
Edwards Lifesciences (EW) reaffirmed original 2024 total company constant currency sales growth guidance of 8% to 10%. The company is projecting 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50, and TAVR sales of $4.1 - $4.4 billion.
"In 2026 and beyond, strong total company sales growth will be driven by meaningful catalysts with the potential to change aortic stenosis treatment, including EARLY TAVR and the expected successful outcome from the FDA-approved PROGRESS pivotal trial," said Bernard Zovighian, Edwards' CEO.
For comments and feedback contact: editorial@rttnews.com